SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

28 Oct 2022 Evaluate
A decrease in the sales to Rs. 649.53 millions was observed for the quarter ended September 2022. The sales stood at Rs. 784.97 millions during the similar quarter previous year.Net profit of the cmpany stood at Rs. 49.64 millions for the quarter ended September 2022 a decline of -65.02% from Rs. 141.89 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 88.50 millions from 214.34 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 649.53 784.97 -17.25 1278.90 1544.06 -17.17 3186.67 2552.07 24.87
Other Income 40.99 48.87 -16.12 77.46 98.09 -21.03 126.40 115.21 9.71
PBIDT 88.50 214.34 -58.71 119.73 494.83 -75.80 782.09 852.30 -8.24
Interest 1.20 4.02 -70.15 6.18 7.72 -19.95 15.62 18.40 -15.11
PBDT 87.30 210.32 -58.49 113.55 487.11 -76.69 766.47 833.90 -8.09
Depreciation 20.19 19.56 3.22 39.77 38.89 2.26 76.73 73.94 3.77
PBT 67.11 190.76 -64.82 73.78 448.22 -83.54 689.74 759.96 -9.24
TAX 17.47 48.87 -64.25 19.02 112.84 -83.14 167.28 205.28 -18.51
Deferred Tax 1.62 4.87 -66.74 -5.58 8.84 -163.12 -4.22 14.58 -128.94
PAT 49.64 141.89 -65.02 54.76 335.38 -83.67 522.46 554.68 -5.81
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 13.63 27.31 -50.10 9.36 32.05 -70.79 24.54 33.40 -26.51

NGL Fine-Chem Share Price

2816.00 145.65 (5.45%)
09-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1105.75
Lupin 2263.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×